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Abstract
Background: Platelet transfusion is universally employed in acute leukemia. Platelet concentrate
supernatants contain high concentrations of biologic mediators that might impair immunity. We
investigated whether washed platelet and red cell transfusions could improve clinical outcomes in
adult patients with acute leukemia.
Methods: A pilot randomized trial of washed, leukoreduced ABO identical transfusions versus
leukoreduced ABO identical transfusions was conducted in 43 adult patients with acute myeloid or
lymphoid leukemia during 1991–94. Primary endpoints to be evaluated were platelet transfusion
refractoriness, infectious and bleeding complications and overall survival.
Results: There were no significant differences in infectious or major bleeding complications and
only one patient required HLA matched platelet transfusions. Minor bleeding was more frequent
in the washed, leukoreduced arm of the study. Confirmed transfusion reactions were more
frequent in the leukoreduced arm of the study. Overall survival was superior in the washed arm of
the study (40% versus 22% at 5 years), but this difference was not statistically significant (p = 0.36).
A planned subset analysis of those ≤50 years of age found that those in the washed, leukoreduced
arm (n = 12) had a 75% survival at five years compared with 30% in the leukoreduced arm (n = 10)
(p = 0.037)
Conclusion: This study provides the first evidence concerning the safety and efficacy of washed
platelets, and also raises the possibility of improved survival. We speculate that transfusion of
stored red cell and platelet supernatant may compromise treatment, particularly in younger
patients with curable disease. Larger trials will be needed to assess this hypothesis.
Background
In recent years, data have accumulated that platelet trans-
fusion refractoriness and transfusion reactions in patients
with hematologic malignancies can be reduced by use of
leukoreduced [1-3] and/or ABO identical [4,5] platelet
transfusions. Preliminary data also suggest that use of
ABO identical [6] and leukoreduced transfusions [7]
might potentially affect clinical outcomes such as survival
and bacterial infection. Data also exist suggesting that
alloimmunization to plasma antigens may play a role in
platelet transfusion refractoriness, [8] and that removal of
plasma supernatant can reduce the incidence of reactions
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to platelet transfusions [9]. One method for removing
plasma supernatant from platelet concentrates is washing.
However, washing involves loss of perhaps 20% of plate-
lets. No clinical trial data exist comparing washed and
unwashed platelet transfusions in terms of efficacy in pre-
venting bleeding, and safety, in terms of unforeseen com-
plications of transfusing platelets subjected to an
additional manipulation.
Over the last two decades it has become apparent that all-
ogeneic blood transfusions can modify host immunity
and clinical outcomes [10]. Epidemiologic data, animal
models, and, in some instances, randomized clinical trials
demonstrate that transfusions reduce solid organ allograft
rejection and repetitive spontaneous abortions, and
increase the likelihood of post-operative bacterial infec-
tions [11]. Perhaps most controversial is the association
between blood transfusion and cancer recurrence, which
has been convincingly demonstrated in some animal
models, [12] but for which randomized clinical trial evi-
dence is lacking. We observed that patients with cancer
had significantly greater recurrence rates if transfused with
whole blood [13,14] rather than red cell concentrates, and
this epidemiologic association has been confirmed by
others [15].
Platelet transfusions are almost universally used in the
supportive care of acute leukemia in adults. The original
study design hypothesized a potential benefit from
removing soluble immunomodulatory mediators in red
cell and platelet concentrates derived from plasma and
white cells. White cells and their secreted products are
now largely removed prior to storage through filtration.
However, there is now reason to be concerned about sol-
uble platelet derived substances that would not be
removed by pre-storage leukoreduction, as well as immu-
nomodulatory mediators from plasma itself, such as IgG
and soluble HLA antigens. More recent data document
that stored platelet concentrate supernatants accumulate
striking levels of biologic response modifiers during stor-
age, including vascular endothelial growth factor (VEGF),
soluble CD40L, histamine and transforming growth fac-
tor (TGF-β1) [16-18]. There is reason to believe that these
molecules are infused at what may be clinically significant
doses, and might alter recipient immune function.
sCD40L has recently been demonstrated to be a growth
promoting and apoptosis inhibiting factor for leukemic
cells in vitro [19].
Platelet transfusions are given to patients undergoing
myelotoxic chemotherapy for acute leukemia over a two
to three week period when the peripheral blood immune
system is regenerating. We speculated that platelet trans-
fusions, in addition to causing platelet refractoriness and
transfusion reactions, might impair anti-leukemic immu-
nity because allogeneic transfusions have been shown to
favor type 2 immunity (e.g., characterized by cytokines
such as IL4 and IL10) and suppress type 1 cellular immu-
nity (e.g., IL2, γ-interferon and TNF-α) [20,21]. There are
data suggesting that host type 1 immunity may be impor-
tant in the eradication of residual malignant cells after
therapy [22].
To investigate the possible efficacy of washed platelet
transfusions in preventing platelet refractoriness, transfu-
sion reactions, bleeding and improving long term survival
in adult acute leukemia, we performed a randomized trial
in patients receiving either washed, leukoreduced, ABO
identical platelet and red cell transfusions compared with
our standard protocol of leukoreduced, ABO identical
transfusions.
Methods
Patients
The diagnosis of acute leukemia was based upon labora-
tory results from our hematopathology laboratory. Only
patients receiving chemotherapy with curative intent were
included. Three patients died before receiving a full course
of induction therapy but are included in the data. Data
retrieval of clinical information was done in a blinded
fashion. Patients and clinicians were not blinded as to
study allocation due to the obvious difference in packag-
ing of washed versus unwashed transfusions.
For acute myeloid or undifferentiated leukemia treatment
invariably involved initial remission induction attempts
with seven days of cytosine arabinoside and three days of
an anthracycline. Patients with acute lymphoid leukemia
received vincristine and prednisone, as well as other
drugs. Patients with high risk features or those who failed
to achieve remission received additional courses of induc-
tion therapy and/or additional agents depending on
attending physician preference. Cytogenetic results, when
available, were classified retrospectively according to a
currently used scheme [23]. All stem cell transplants per-
formed involved autologous bone marrow or that from an
HLA identical sibling.
Patients entering remission also typically underwent con-
solidation therapy and bone marrow transplant depend-
ing on age, performance status, availability of a sibling
HLA matched allogeneic donor and other factors. Our
institutional review board for studies involving humans
approved the study protocols and informed consent doc-
uments. Once placed on a particular transfusion protocol,
as described below, a patient received only transfusions of
that type throughout their treatment. This included con-
solidation, transplant and relapses, continuing until they
were cured or died of their leukemia.BMC Blood Disorders 2004, 4:6 http://www.biomedcentral.com/1471-2326/4/6
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In 1991–94, 43 patients participated in a randomized trial
of ABO identical, leukoreduced versus ABO identical, leu-
koreduced, plasma reduced (washed) transfusions. Study
endpoints were platelet transfusion refractoriness, total
platelet transfusion requirements during induction ther-
apy, infections during induction therapy and overall sur-
vival. Randomization was arranged by our Department of
Biostatistics employing computer generated random
assignments and a blocked design with separate, sequen-
tial, sealed, opaque envelopes for patients with diagnoses
of acute myeloid (AML) or acute lymphoid (ALL) leuke-
mias. Leukoreduction for all patients was by post-storage,
bedside filtration with Pall filters (RC50 and PL100), and
plasma reduction of both red cell and platelet transfu-
sions was by saline washing using the Cobe 2991 by a pre-
viously published method [24]. Neither transfusion
service nor clinical staff was blinded to study assignment
after opening of the envelope, but this was not considered
essential as major clinical outcomes (platelet transfusion
responsiveness and survival) were unlikely to be affected
by staff knowledge of study assignment. Power calcula-
tions were not performed as the trial was considered pri-
marily a feasibility trial. All adult patients with acute
leukemia who were to receive full dose induction chemo-
therapy would be recruited during a three year period
beginning in early 1991. A maximum of 60 patients were
expected to be accrued.
Transfusion practice was consistent during the period of
the study, employing almost exclusively whole blood
derived random platelet concentrates, either ABO identi-
cal, leukoreduced, or washed, ABO identical, leukore-
duced, according to protocol. Prophylactic transfusions
were consistently given at morning platelet counts of <20
× 109/l and usually prior to invasive procedures at <50 ×
109/l. Protocol violations in which patients received a
transfusion of the incorrect type were <0.5% of all trans-
fusions. All transfusions were treated with 2500 centigray
gamma irradiation. We did not collect data on storage
time of the red cells or platelets transfused in the study.
Patients were to be excluded from the analysis if they did
not have acute leukemia or died prior to randomization.
Since randomization occurred upon admission to the
hospital with the diagnosis of suspected acute leukemia,
some patients were found to have other diseases after ran-
domization. These exclusions involved two patients who
were randomized to the unwashed group but found not to
have acute leukemia upon further investigation. Subgroup
analysis was planned for patients ≤50 years of age because
they are known to have substantially better prognosis, and
for patients with acute myeloid leukemia, who may have
a greater risk of HLA alloimmunization. Fifty years of age
was also the maximal age for allogeneic bone marrow
transplantation in patients with acute leukemia at the
time of the study.
Data were collected by a blinded coauthor (JMH) from
medical record review of the admission for initial induc-
tion, and follow-up data on survival obtained from the
local tumor registry. The clinical data for blood compo-
nent use and morbidity were collected only for the initial
admission to achieve treatment time comparability.
Bleeding was evaluated for the initial admission for remis-
sion induction, and defined as minor (1–2 days not
requiring any therapeutic intervention such as wound site
hematoma, guaiac positive stools, mild epistaxis not
requiring transfusion nor packing, etc.) or major (requir-
ing transfusion of red cells or otherwise mandating surgi-
cal or other therapeutic intervention). Refractoriness was
evaluated for the entire duration of a patient's transfusion
therapy until cessation of transfusions or death, and
defined as the need for HLA matched platelet transfu-
sions, as determined by the attending hematologist.
Transfusion reactions were reported at the discretion of
the nursing staff and evaluated by Transfusion Service res-
idents who were not blinded as to the component
received. A new fever or new rigors occurring during or
shortly after a transfusion was considered a reaction
whereas a fever or rigor that occurred shortly before the
transfusion started was considered unrelated.
Statistical methods
Statview 5.0 (SAS Institute, Cary, NC) was employed to
calculate survival curves by the Kaplan-Meier method and
Cox proportional hazards regressions. For continuous var-
iables, the Mann-Whitney test was used for bivariate com-
parisons, and for categorical variables, Fisher's exact test
or Chi square with continuity correction were employed
as appropriate. No corrections were made for multiple
comparisons, because except for the major outcome vari-
ables of survival, platelet refractoriness, infectious compli-
cations and platelet utilization, the data comparisons are
considered exploratory.
Results
The demographic pre-treatment and initial hospitaliza-
tion clinical outcomes data for patients in the study are
shown in Tables 1 and 2, and the long term survival
results are shown in the Kaplan-Meier plot in figure 1.
Except for cytogenetics there were few differences between
the two cohorts in terms of pre-treatment variables. Of
those who had cytogenetics successfully determined there
were more patients with poor risk cytogenetics in the
washed arm (11 of 18; 61%) than in the unwashed arm (2
of 9; 22%) of the study (p = 0.11 by Fisher's exact test).
There was no statistically significant increased need for
red cell or platelet transfusions, nor increased bleeding in
the patients receiving washed transfusions.BMC Blood Disorders 2004, 4:6 http://www.biomedcentral.com/1471-2326/4/6
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Clinically evident bleeding was uncommon (8 of 43
patients, 19%) and major bleeding occurred in only 2 of
43 patients (5%). Minor bleeding was more common in
those receiving washed platelets (6 of 25, 24%) than
unwashed (0 of 18, 0%) (p = 0.03 by Fisher's exact test)
but major bleeding occurred in only one patient in each
arm of the study (1 of 25 versus 1 of 18; not significantly
different). Bleeding was in all instances related to specific
anatomic lesions, such as minor epistaxis, hematomas at
the site of trauma or invasive procedures, or guaiac posi-
tive stools. For six patients these mild bleeding episodes
were only seen on one or two days during their admission,
without generalized petechiae or purpura. One patient in
the washed arm had melena for five days, which resolved.
The only life threatening bleeding was non-fatal and
occurred in one patient in the unwashed arm of the study
who experienced eight days of hemoptysis and received
416 units of platelets and 52 units of red cells during
induction therapy. Bleeding did not influence overall sur-
vival at last follow-up, which was 38% in those who had
bleeding and 35% in those patients with no bleeding (p =
0.94 by logrank test). Patients with bleeding required
more platelet (mean of 141 ± 118) (1 SD) and red cell
transfusions (21 ± 13) than patients with no bleeding (61
± 44 platelets and 15 ± 7 red cells), but this was almost
exclusively due to the one patient in the unwashed arm of
the study with eight days of hemoptysis. When this
patient was removed from the analysis, the patients with
Table 1: Demographic and pre-treatment clinical variables according to type of transfusions given.
ABO Matched, Leukoreduced ABO Matched, Leukoreduced, 
Washed
P value by Mann Whitney or 
Fisher's Exact Test
N1 8 2 5
Age 48 ± 23 47 ± 17 0.89
Male 9 (50%) 11 (44%) 0.76
ALL/AML 4/14 5/20 0.99
Antecedent Hematologic Disorder (MDS) 0 of 18 (0%) 3 of 25 (12%) 0.25
Favorable Risk Cytogenetics 1 (6%) 0 (0%) 0.09*
Standard Risk Cytogenetics 6 (33%) 7 (28%)
Poor Risk Cytogenetics 2 (11%) 11 (44%)
Unknown Cytogenetics 9 (50%) 7 (28%)
Admission Blast Count (×1000/µl) 25 ± 36 23 ± 41 0.59
All data are mean ± 1 SD. MDS = myelodysplastic syndrome
*For cytogenetics as a category overall
Table 2: Outcome variables according to type of transfusions received.
ABO Matched, Leukoreduced ABO Matched, Leukoreduced, 
Washed
P value by Mann Whitney or 
Fisher's Exact Test
N1 8 2 5
Red Cells (units) 16 ± 12 16 ± 6.2 0.21
Platelets (units) 84 ± 100 73 ± 49 0.64
Platelets/Day (units) 1.8 ± 1.2 1.9 ± 1.3 0.90
Red Cells/Day (units) 0.4 ± 0.1 0.4 ± 0.3 0.39
Platelets/Red Cell 4.6 ± 2.4 4.4 ± 2.5 0.74
Courses of Induction Chemotherapy 1.3 ± 0.6 1.3 ± 0.4 0.90
Length of stay (days) 43 ± 24 42 ± 17 0.47
Received HLA matched platelets 0 of 18 (0%) 1 of 25 (4%)
Days with fever >37 degrees Celsius 16 ± 11 15 ± 9.2 0.90
Days of antibiotics 36 ± 26 36 ± 18 0.25
Positive Microbial Cultures 1.0 ± 1.2 1.3 ± 1.4 0.53
Days with bleeding 0.62 ± 2.2 0.58 ± 1.2 0.19
Reported Transfusion Reactions per Patient 0.4 ± 0.8 0.4 ± 0.7 0.91
Complete remission at discharge 12 of 18 (67%) 17 of 25 (68%) 1.00
Received BMT 8 of 18 (44%) 14 of 25 (56%) 0.54
All continuous variables results are means ± 1 SD.BMC Blood Disorders 2004, 4:6 http://www.biomedcentral.com/1471-2326/4/6
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bleeding received no more transfusions than those with-
out bleeding.
Reported numbers of transfusion reactions were similar in
both arms of the study (a mean of 0.4 per patient). In the
washed arm of the study there were eight transfusion reac-
tions reported due to intercurrent fever and two allergic
reactions (rash and/or urticaria) to unwashed platelet
transfusions given in violation of protocol due to clinical
urgency. In the unwashed arm of the study there were
three transfusions with intercurrent fever and four allergic
reactions. Reactions were reported in 7 of 25 (28%) of
patients in the washed study arm and 7 of 18 (39%) of the
patients in the unwashed arm (p = 0.52). When evaluated
by the transfusion medicine resident, seven of the reac-
tions in the washed arm were considered to be pre-exist-
ing fever and the reported reaction likely unrelated to
transfusion. When only "on protocol" transfusions
judged causally related by a blood bank physician are con-
sidered, the patients in the washed arm were less likely to
experience reactions (1 of 25; 4%) than patients in the
unwashed arm (7 of 18; 39%) (p = 0.0058 by Fisher's
exact test). During the course of the treatment, three of 18
patients randomized and analyzed in the unwashed arm
had severe or repeated transfusion reactions and were
placed on a washed protocol for future transfusions.
As determined by a Cox proportional hazards regression,
survival was not associated significantly with type of
leukemia (p = 0.37), cytogenetic results (p = 0.63), or
receipt of washed blood transfusions (p = 0.62) but was
significantly associated with age (p = 0.0002), with
younger patients surviving longer.
Because long-term survival in acute leukemia is uncom-
mon in those over the age of 50–60 years, we also per-
formed a planned subset comparison of the 22 patients in
the trial ≤50 years of age. We recognized that this subset
would be small, rendering statistical analysis more diffi-
cult. These results are shown in figure 2, along with demo-
graphics on these patients in Tables 3 and 4.
There were more patients with ALL (p = 0.32) and more
patients with poor risk cytogenetics in the washed arm of
the study (p = 0.09). Otherwise there were few differences
between the patients ≤50 years of age in the two cohorts.
Patients in the washed arm had significantly better overall
survival and required fewer platelets per day or per red cell
Results of the randomized trial of washed (n = 25 patients) versus unwashed (n = 18) platelet transfusions Figure 1
Results of the randomized trial of washed (n = 25 patients) versus unwashed (n = 18) platelet transfusions. 
There is no significant difference in survival by the logrank test (p = 0.36). Censored data points are patients remaining alive.BMC Blood Disorders 2004, 4:6 http://www.biomedcentral.com/1471-2326/4/6
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transfused than patients in the unwashed arm. There were
no significant differences in bleeding, use of growth fac-
tors or white cell transfusions between the two arms of the
study, in either the entire or younger cohorts (data not
shown but available from the authors on request).
Keeping in mind the extremely small number of patients
involved, a Cox proportional hazards regression was
performed on these younger patients in the randomized
trial. Receipt of washed transfusions was a significant pre-
dictor of longer survival (p = 0.011), as was cytogenetics
(patient's with unknown cytogenetics having poorer
survival, p = 0.027) but age and type of leukemia were not
statistically significant predictors of survival time.
The survival of all patients ≤50 restricted to those with
AML is shown in Figure 3 confirming that the patients in
Survival in those patients in the randomized trial of washed (n = 12) versus unwashed (n = 10) platelet transfusions ≤50 years  of age is plotted by the Kaplan-Meier method Figure 2
Survival in those patients in the randomized trial of washed (n = 12) versus unwashed (n = 10) platelet transfu-
sions ≤50 years of age is plotted by the Kaplan-Meier method. Those in the washed group had significantly better sur-
vival (p = 0.037 by logrank test). Two of the patients in the washed group were both alive and in remission at last recorded 
follow-up of 47 months. Two of the patients in the unwashed arm were both alive and in remission at last recorded follow-up 
of 116 months. At the minimum follow-up time of 41 months 9 of 12 patients in the washed arm were alive and in remission, 
as compared with 3 of 10 in the unwashed arm.
Table 3: Demographic and pre-treatment clinical variables according to type of transfusions given in those ≤50 years of age.
ABO Matched, Leukoreduced ABO Matched, Leukoreduced, 
Washed
P value by Mann Whitney or 
Fisher's Exact Test
N1 0 1 2
Age 30 ± 9.4 32 ± 9.5 0.77
Male 5 (50%) 6 (50%) 1.00
ALL/AML 1/9 4/8 0.32
Antecedent Hematologic Disorder (MDS) 0 of 10 (0%) 0 of 12 (0%) 1.00
Favorable Risk Cytogenetics 0 (0%) 0 (0%) 0.09
Standard Risk Cytogenetics 5 (33%) 2 (28%)
Poor Risk Cytogenetics 1 (11%) 6 (44%)
Unknown Cytogenetics 4 (50%) 4 (28%)
Admission Blast Count (×1000/µl) 29 ± 49 29 ± 49 0.56
All data are mean ± 1 SD. MDS = myelodysplastic syndromeBMC Blood Disorders 2004, 4:6 http://www.biomedcentral.com/1471-2326/4/6
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the washed arm did not survive longer solely because of
the larger number of patients with ALL in that arm of the
study.
In the subset of all patients ≤50 years of age with either
type of leukemia who both achieved a complete remission
and also received definitive post-remission therapy in the
form of bone marrow transplantation, the survival in
patients receiving washed transfusions (n = 12) was signif-
icantly better than those receiving unwashed transfusions
(n = 8) (p = 0.031 by log rank test) (graph not shown).
Table 4: Outcome variables according to type of transfusions received in those ≤50 years of age.
ABO Matched, Leukoreduced ABO Matched, Leukoreduced, 
Washed
P value by Mann Whitney or 
Fisher's Exact Test
N1 0 1 2
Red Cells (units) 20 ± 14 16 ± 6.2 0.93
Platelets (units) 127 ± 121 69 ± 52 0.23
Platelets/Day (units) 2.4 ± 1.1 1.4 ± 1.0 0.039
Red Cells/Day (units) 0.4 ± 0.06 0.4 ± 0.1 0.39
Platelets/Red Cell 5.9 ± 2.0 4.1 ± 3.0 0.069
Courses of Induction Chemotherapy 1.5 ± 0.8 1.2 ± 0.4 0.31
Length of stay (days) 50 ± 30 47 ± 18 0.56
Received HLA matched platelets 0 of 10 (0%) 0 of 12 (0%) 1.00
Days with fever >37 degrees Celsius 19 ± 12 14 ± 9.1 0.36
Days of antibiotics 44 ± 31 40 ± 21 0.74
Positive Microbial Cultures 1.1 ± 1.3 1.4 ± 1.5 0.76
Days with bleeding 1.0 ± 2.8 0.46 ± 0.67 0.36
Transfusion Reactions per Patient 0.4 ± 0.7 0.4 ± 0.5 0.73
Complete remission at discharge 9 of 10 (90%) 11 of 12 (92%) 1.00
Received BMT 8 of 10 (80%) 11 of 12 (92%) 0.57
All continuous variables results are means ± 1 SD.
Survival in those patients in the randomized trial of washed (n = 8) versus unwashed (n = 9) platelet transfusions ≤50 years of  age with AML is plotted by the Kaplan-Meier method Figure 3
Survival in those patients in the randomized trial of washed (n = 8) versus unwashed (n = 9) platelet transfu-
sions ≤50 years of age with AML is plotted by the Kaplan-Meier method. Those in the washed group experienced 
better survival but this was not statistically significant (p = 0.10 by logrank test). At a minimum follow-up of 41 months, 6 of 8 
patients in the washed arm were in remission and alive compared with 3 of 9 in the unwashed arm (two of the patients in the 
unwashed arm were alive and in remission at 116 months).BMC Blood Disorders 2004, 4:6 http://www.biomedcentral.com/1471-2326/4/6
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Discussion and conclusions
To our knowledge, these data represent the first rand-
omized trial of washed platelet transfusions in any setting.
The issues of the efficacy and safety of washed platelet
transfusions are of importance because (1) some patients
require plasma-reduced transfusions to treat allergic or
febrile reactions, (2) new methods of viral and bacterial
pathogen-inactivation for transfusions may require wash-
ing prior to transfusion, and (3) a growing body of evi-
dence suggests that immunologically important
molecules are present in the stored supernatant of blood
transfusions that might, speculatively, affect clinical
outcomes. Our study design was less likely to detect a ben-
efit of platelet washing because, unlike many centers, we
routinely use ABO identical platelet transfusions for
patients with leukemia. There is evidence from two small
randomized trials in leukemia that this reduces refractori-
ness [4,5] and increases survival [6]. Preliminary results
exist that ABO matching may also reduce morbidity and
mortality in surgical patients [25].
There was no apparent benefit to washed transfusions in
terms of reduced platelet transfusion refractoriness,
reduced bacterial infections, reduction in reported febrile
or allergic transfusion reactions or reduced length of stay.
Confirmed transfusion reactions were less frequent in the
washed arm of the study, and 15% of the patients in the
leukoreduced arm of the study had severe or repeated
reactions that led to their receiving washed transfusions,
which abrogated those reactions. Our data do provide evi-
dence, for the first time, that washed platelet transfusions
are probably as safe and efficacious as standard leukore-
duced transfusions. The mean number of days with
bleeding was marginally but not significantly reduced in
the patients in the washed group, as were the number of
platelet transfusions needed per day in younger patients,
and the ratio of platelet transfusions to red cell transfu-
sions. However, there was more minor bleeding in the
washed group raising the possibility that washed platelets
are slightly less effective. However, the prevalence of
major bleeding requiring treatment was the same in each
group and very low (<5%). The only life threatening hem-
orrhage in these 43 patients occurred in a patient in the
leukoreduced arm.
This study is also the first attempt to investigate whether
transfusion practices during initial induction therapy are
associated with changes in overall survival in acute leuke-
mia in adults. The underlying rationale for studying this
issue are observations demonstrating that allogeneic
transfusions alter host T cell and natural killer cell
immune function in surgical patients and experimental
animals [11]. The major causes of death in adults with
leukemia are failure to achieve complete remission, and
relapse after achieving complete remission. There is some
evidence from the allogeneic bone marrow transplant lit-
erature that host immune function may play a role in pre-
venting relapse during the post-treatment period, but
there are no data that demonstrate a role for the immune
system in achieving complete initial remissions [26]. Our
study found no difference in complete remission induc-
tion success rates with differing transfusion protocols, but
does support the possibility of an association between
type of red cell and platelet preparation transfused and
long term survival.
Large numbers of red cell and platelet transfusions are
given to patients with acute leukemia during the period of
recovery from aplasia that is caused by cytotoxic chemo-
therapy given during remission induction. Additional
transfusions are given during consolidation and bone
marrow or peripheral blood stem cell transplantation.
Many of these transfusions occur during the period when
at least the bone marrow and peripheral blood compart-
ments of the immune system are reconstituting and might
be susceptible to the immunomodulatory effects of trans-
fusions. Both white cell and platelet-derived mediators are
present in the transfused red cells as well as platelets.
Prestorage leukoreduction (not employed in this study)
removes the vast majority of the white cells and platelets
from stored red cells, and red cell concentrates would be
expected to have much lesser concentrations of biologic
mediators, even without washing. Platelet derived media-
tors would, of course, still be present in prestorage leuko-
reduced platelet concentrates.
Transfusions are known to cause suppression of type 1 cel-
lular immunity and upregulation of type 2 humoral
immunity [20,21]. Such immune deviation could, specu-
latively, impair host defenses provided by T cells, den-
dritic cells and natural killer cells that might be involved
in the eradication or control of residual tumor. Potential
mediators of down regulation of cellular immunity by
transfusions include allogeneic white cells, red cells or
platelets, ABO antigen-antibody complexes formed after
repeated ABO non-identical platelet transfusions, and the
stored supernatant of, in particular, platelet concentrates.
Transfusion of stored platelet supernatant plasma might
be hypothesized to mediate such effects by immunoregu-
latory and tumor growth promoting factors, such as
sCD40L or angiogenic factors such as VEGF [16-18].
Leukoreduction filters remove white cells from the trans-
fused blood components. In the case of pre-storage leuko-
reduction, filtration also removes some of the biologic
response modifiers secreted by white cells during storage.
Platelet concentrate supernatant contains large amounts
of mediators such as soluble CD40L (CD154), VEGF,
TGF-β1, histamine and other biologic response modifiers
that might impair cellular immunity [16-18]. WashingBMC Blood Disorders 2004, 4:6 http://www.biomedcentral.com/1471-2326/4/6
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immediately prior to transfusion removes most soluble
materials from the transfused platelet and red cell transfu-
sions, including those released during storage from the
platelets, red cells and white cells. Our data provide initial
support for the novel hypothesis that changing transfu-
sion practices could play a role in long-term survival in
acute leukemia, particularly in younger patients who can
be potentially cured.
There are distinct limitations to what can be concluded
from our data. The number of patients studied is very
small and almost all of them had AML. The statistically
significant improvement in survival in patients ≤50 years
of age with AML who had unusually good survival repre-
sents a subset analysis, not a primary outcome group and
thus may represent the play of chance. The survival of
75% of any cohort of adult patients with acute leukemia
for 4–5 years is a distinctly unusual circumstance [27].
This could be due to the benefits of receiving washed
transfusions, but could also be a chance occurrence in a
small cohort of patients. Our overall survival in all
patients of 40% in the larger cohort of patients of all ages
and risk factors in the washed arm is equivalent to the best
survival that has been reported in low risk, younger
patients in other trials from the period of the early 1990s
[27]. As shown in the figures, there was only one relapse
and death that occurred at beyond five years in our
cohorts, with a number of patients alive and in remission
at 5–12 years after diagnosis. Thus it appears that if there
was benefit from washing of transfusions, it probably
involves an increased likelihood of durable remission,
rather than purely delaying relapse.
These data, however promising, raise hypotheses for addi-
tional testing rather than proving a principle. If transfu-
sion practice impacts anti-leukemic immunity, and/or
survival as our data suggest, a moderate sized randomized
clinical trial should be able to confirm this in relatively
few years. This is a propitious time for such trials as the
need for prophylactic platelet transfusion therapy is being
revisited. The question is being raised as to whether plate-
let transfusions in non-bleeding patients are truly neces-
sary or need be as frequent as currently employed in this
disease [28]. One strategy for randomized trials would be
to randomize patients to only therapeutic platelet transfu-
sions (transfusion only for bleeding manifestations) ver-
sus current standard practice of prophylactic transfusions
at a set threshold such as 10 × 109/µl.
Platelet washing is time consuming, delaying transfusion
by about 2.5–3 hours, may present an additional oppor-
tunity for bacterial contamination, and involves some loss
of platelets (about 20%). Platelet washing may not be fea-
sible in clinically urgent situations. Direct costs are mod-
est, at less than $40 per transfusion. Washing adds about
$500–2000 to the total cost of caring for patients with
acute leukemia in our center from diagnosis to cure or
death. This is less than 0.5–1% of the total costs of treating
AML or ALL with curative intent. There are few or no
proven side effects of platelet washing other than reduced
dose of platelets transfused. There are some additional
potential clinical benefits of washing including a reduced
likelihood of transfusion complications such as febrile
non-hemolytic transfusion reactions, transfusion-related
acute lung injury, and allergic reactions. These prelimi-
nary data, albeit from a very small number of patients,
raise the possibility that some patients with acute leuke-
mia might benefit from washed transfusions. Larger stud-
ies are indicated to explore this possibility.
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